Home LiteratureArticle Details
PMID: 7919965 Published · ppublish English Clinical Trial Comparative Study Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov't

HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2).

Melanoma research ·Vol. 4 ·No. 3 ·1994-06-00 ·Pages 191-4

Scheibenbogen C, Keilholz U, Mytilineos J, Suciu S, Manasterski M, Hunstein W

Abstract

MHC-restricted recognition of melanoma cells by cytotoxic T lymphocytes is an important mechanism in vitro. Several HLA alleles can function as restriction elements for melanoma cell recognition. In this study we investigated whether there is a correlation between responsiveness of patients with metastatic melanoma (MM) to immunotherapy and the HLA type of the patient. Seventy-two patients received immunotherapy with IFN-alpha and IL-2 according to two different schedules with an overall response rate of 24%. In 54 patients, including 16 responders and 16 patients with stable disease, in whom peripheral blood lymphocytes were available, we determined HLA haplotypes. As a control group we prospectively determined HLA types in 67 melanoma patients of all stages who underwent surgery or received chemotherapy and of 126 healthy donors from our blood bank. Two HLA alleles that have been shown to function as restriction elements in vitro were observed more frequently in responding patients, namely Cw7 (p = 0.014) and A1 (p = 0.19). No association was found for A2 and B44. These observations provide evidence that the responsiveness of MM to immunotherapy with IL-2 is associated with certain HLA types, suggesting an important role of HLA-restricted T lymphocytes for IL-2-induced tumour regression.

MeSH Terms
Alleles Blood Donors Drug Administration Schedule Genes, MHC Class I HLA-A Antigens/analysis HLA-B Antigens/analysis HLA-C Antigens/analysis Histocompatibility Antigens Class I/analysis Humans Immunotherapy/methods Interferon Type I/administration & dosage,therapeutic use Interleukin-2/administration & dosage,therapeutic use Lymphocytes/immunology Melanoma/genetics,immunology,therapy Predictive Value of Tests Recombinant Proteins
Chemicals
HLA-A Antigens HLA-B Antigens HLA-C Antigens Histocompatibility Antigens Class I Interferon Type I Interleukin-2 Recombinant Proteins
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Scheibenbogen C
Department of Medicine V (Hematology/Oncology), University of Heidelberg, Germany.
Keilholz U
Mytilineos J
Suciu S
Manasterski M
Hunstein W
Article Info
Journal
Melanoma research
Abbr.
Melanoma Res
ISSN
0960-8931
Published
1994-06-00
Pages
191-4
Language
English
Region
England
NLM ID
9109623
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com